Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

RCT-TCZ-COVID-19, 2021
 
NCT04346355
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
60/66 inconclusive
    RECOVERY, 2021
     
    NCT04381936
    RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
    2022/2094 conclusif
    • demonstrated 14 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 15 % decrease in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
    Soin AS (COVINTOC), 2021
     
    CTRI/2020/05/025369
    RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
    90/90 inconclusive
      Dongsheng Wang, 2020
       
      ChiCTR2000029765
      RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
      33/32 safety concern
      • statistically significant 8.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
      Colaneri, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
      21/21 inconclusive
        HNF Hospital Tocilizumab multidisciplinary team, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
        20/25 suggested
        • suggested 87 % decrease in death or transfer to ICU but with a very low degree of certainty due to critical risk of bias
        Martinez-Sanz, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
        260/969 suggested
        • suggested 66 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
        Tsai, 2020 OBStocilizumab controlCOVID 19 hospitalizedserious
        66/66 inconclusive

          COVID-19 mild to moderate meta-analysis

          CORIMUNO-19, 2020
           
          NCT04331808
          RCTtocilizumab standard of careCOVID-19 mild to moderatesome concern
          64/67 inconclusive
            EMPACTA, 2020
             
            NCT04372186
            RCTtocilizumab placeboCOVID-19 mild to moderatesome concern
            259/129 conclusif
            • demonstrated 44 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
            • suggested 45 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
            Capra, 2020 OBStocilizumab controlCOVID-19 mild to moderatecritical
            62/23 suggested
            • suggested 96 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

            COVID-19 severe or critically meta-analysis

            Lescure (Sarilumab 200mg), 2021
             
            NCT04327388
            RCTsarilumab low dose (200mg)placeboCOVID-19 severe or criticallysome concern
            161/86 inconclusive
            • inconclusive 3 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
            Lescure (Sarilumab 400mg), 2021
             
            NCT04327388
            RCTsarilumabplaceboCOVID-19 severe or criticallysome concern
            173/86 inconclusive
              Lescure (Sarilumab 400mg), 2021
               
              NCT04327388
              RCTsarilumab high dose (400mg)placeboCOVID-19 severe or criticallysome concern
              173/86 inconclusive
                REMAP-CAP sarilumab, 2021
                 
                NCT02735707
                RCTsarilumabstandard of careCOVID-19 severe or criticallysome concern
                48/402 conclusif
                • demonstrated 76 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
                • suggested 86 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
                REMAP-CAP tocilizumab, 2021
                 
                NCT02735707
                RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                353/402 conclusif
                • suggested 30 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
                • demonstrated 64 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
                Veiga, 2021
                 
                NCT04403685
                RCTtocilizumab controlCOVID-19 severe or criticallysome concern
                65/64 safety concern
                • safety concern with 1.7-fold increase in deaths (not statistically significant)
                BACC Bay Tocilizumab Trial, 2020
                 
                NCT04356937
                RCTtocilizumab placeboCOVID-19 severe or criticallylow
                161/81 inconclusive
                • inconclusive 17 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
                COVACTA (Rosas), 2020
                 
                NCT04320615
                RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
                301/151 suggested
                • inconclusive 19 % increase in clinical improvement,clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
                Andrew, 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
                198/413 inconclusive
                  ARI-RAF (Della-Torre), 2020 OBSsarilumabcontrolCOVID-19 severe or criticallyNA
                  28/28 inconclusive
                    Biran, 2020 OBStocilizumab controlCOVID-19 severe or criticallyserious
                    210/420 suggested
                    • suggested 36 % decrease in deaths but with a low degree of certainty due to high risk of bias
                    Mathilde, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
                    30/29 suggested
                    • suggested 75 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
                    Rojas-Marte, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
                    96/97 inconclusive
                      Somers, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
                      78/76 safety concern
                      • suggested 45 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                      • statistically significant 2.3-fold increase in superinfection but with a very low degree of certainty due to critical risk of bias
                      TOCI-RAF Study Group (Campochiaro), 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
                      32/33 inconclusive

                        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).